Navenibart Demonstrates Durable Efficacy and Tolerability Across Biological Sexes: Subgroup Analysis from the ALPHA-STAR Trial

navenibart (STAR-0215) - BioCryst Pharmaceuticals

https://events.rdmobile.com/Lists/Details/3220809

Karl Sitz MD 1; Michael Manning MD FAAAAI 2; William Lumry MD FAAAAI 3; Adil Adatia MD 4; William Yang MD FAAAAI 5; Joshua Jacobs MD 6; Theodora Cohen 7; Jessica Best 7; Christopher Morabito 7; Aleena Banerji MD FAAAAI 8

Feb 10, 2026